1. Home
  2. BTE vs PBLS Comparison

BTE vs PBLS Comparison

Compare BTE & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Baytex Energy Corp

BTE

Baytex Energy Corp

HOLD

Current Price

$4.57

Market Cap

3.3B

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$33.05

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BTE
PBLS
Founded
1993
N/A
Country
Canada
United States
Employees
N/A
N/A
Industry
Meat/Poultry/Fish
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.3B
3.6B
IPO Year
2004
2026

Fundamental Metrics

Financial Performance
Metric
BTE
PBLS
Price
$4.57
$33.05
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.3M
576.5K
Earning Date
05-07-2026
N/A
Dividend Yield
1.28%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$7.93
N/A
P/E Ratio
$18.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$25.56
52 Week High
$5.36
$42.49

Technical Indicators

Market Signals
Indicator
BTE
PBLS
Relative Strength Index (RSI) N/A 50.21
Support Level N/A $37.77
Resistance Level N/A $41.34
Average True Range (ATR) 0.00 2.60
MACD 0.00 -0.24
Stochastic Oscillator 0.00 40.29

Price Performance

Historical Comparison
BTE
PBLS

About BTE Baytex Energy Corp

Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: